Abbvie Reports First Provincial Reimbursements for VENCLEXTA in Combination with Azacitidine for Acute Myeloid Leukemia Patients

AbbVie (NYSE: ABBV) has reported an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with azacytidine for treatment of patients that are diagnosed with acute myeloid leukemia that are 75 years or older or individuals who have comorbidities that preclude use of intensive induction chemotherapy.  “Acute myeloid leukemia is a blood cancer with …

Abbvie Reports First Provincial Reimbursements for VENCLEXTA in Combination with Azacitidine for Acute Myeloid Leukemia Patients Read More »